Abstracts tagged "clinical trial"

Abstract Number: 2440 • ACR Convergence 2025
Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study
Anca Askanase¹, Bruno Flamion², Ouali Berkani² and Cecile Dubois², ¹Columbia University Medical Center, New York, NY, ²Viatris Innovation, Allschwil, Switzerland
Background/Purpose: Cenerimod is a selective S1P1 receptor modulator that has the potential to reduce the abnormal immune response seen in Systemic lupus erythematosus (SLE) thereby…
Abstract Number: 2288 • ACR Convergence 2025
Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial
Yuan Xue, Bo Wei, Xiaojing Huang and Rui Ding, Zhongshan Hospital Xiamen University, Xiamen, China (People's Republic)
Background/Purpose: Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor, has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA). This post-hoc study aimed to evaluate…
Abstract Number: 2012 • ACR Convergence 2025
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
ullrich schwertschlag¹, yan yang², Jingfei li³, Roy Wu⁴, adam jin² and William Shi⁵, ¹Atom Therapeutics, PALO ALTO, CA, ²Atom Therapeutics, Suzhou, China (People's Republic), ³Atom Therapeutics, Suzhou, Jiangsu, China (People's Republic), ⁴Atom Bioscience, San Francisco, CA, ⁵Atom Therapeutics, Newark, CA
Background/Purpose: ABP-671 is a novel, selective and potent URAT1 inhibitor in development for the treatment of elevated serum uric acid (sUA) levels and gout.Methods: Subjects…
Abstract Number: 1545 • ACR Convergence 2025
Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
Susan Manzi¹, Ian Bruce², Eric Morand³, Richard Furie⁴, Yoshiya Tanaka⁵, Patricia Puzio⁶, Emon Khan⁷, Jenny Wissmar⁸, Michael Song⁹ and Catharina Lindholm¹⁰, ¹Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁴Division of Rheumatology, Northwell Health, Great Neck, NY, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, MD, ⁷BioPharmaceuticals R&D, Late Respiratory and Immunology, AstraZeneca, Academy House, Cambridge, United Kingdom, ⁸BioPharmaceuticals R&D, Late-Stage Development, Respiratory & Immunology, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Boston, MA, ¹⁰BioPharmaceuticals R&D, Late Clinical Development Immunology, AstraZeneca, Gothenburg, Sweden
Background/Purpose: Intravenous (IV) anifrolumab (300 mg, every 4 weeks [Q4W]) is an approved biologic add-on therapy for moderate to severe SLE;1 a subcutaneous (SC) formulation…
Abstract Number: 1441 • ACR Convergence 2025
Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Hongbin Li¹ and Huilin Li², ¹Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Nei Mongol, China (People's Republic), ²Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic)
Background/Purpose: Vunakizumab, a humanized anti-interleukin-17A monoclonal antibody, has shown significant efficacy and favorable safety in patients with active ankylosing spondylitis (AS), leading to its approval…
Abstract Number: 0720 • ACR Convergence 2025
Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials
Manuel Carpio Tumba¹, Aida Mohamadi², Diana Louden³, Victor Pimentel-Quiroz⁴, Michael Putman⁵, Didem Saygin⁶, Raisa Lomanto Silva⁷ and Sebastian E Sattui⁸, ¹University of Pittsburgh, Pittsburgh, PA, ²Tehran University of Medical Sciences, Tehran, Iran, ³University of Washington, Seattle, WA, ⁴Universidad Científica del Sur, San Isidro, Peru, ⁵The Medical College of Wisconsin, Milwaukee, WI, ⁶Rush University Medical Center, Chicago, IL, ⁷Massachusetts General Hospital, Boston, MA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Randomized controlled trials (RCTs) generate unbiased efficacy estimates and are required for regulatory approval. Understanding the degree to which they include racial, ethnic, sex,…
Abstract Number: 0572 • ACR Convergence 2025
Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
Jean-Guillaume Letarouilly¹, Elnaz Saeedi², Raphaël Hurtubise³, Lija James⁴, Nicola Gullick⁵, Deepak Jadon⁶, William Tillett⁷, Yvonne Sinomati⁴, Laura Tucker⁴, Nadia Mian⁸, Sophia Massa³ and Laura Coates⁹, ¹Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, LILLE, Nord-Pas-de-Calais, France, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, United Kingdom, ⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK, Oxford, United Kingdom, ⁵Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁶Department of Medicine, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁷Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁸BM BS, MMedSc,, Oxford, United Kingdom, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: A treat-to-target (T2T) strategy in psoriatic arthritis (PsA) is supported by International PsA recommendations but not widely practiced in clinic. The aim of the…
Abstract Number: 0777 • ACR Convergence 2025
Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)
Kevin Byram¹, Herman Mann², Danielle Hammond³, Sinisa Savic⁴, Yohei Kirino⁵, Carmelo Gurnari⁶, Mael Heiblig⁷, Thibault Comont⁸, Arsène Mekinian⁹, Mrinal Patnaik¹⁰, Lachelle D. Weeks¹¹, Gary Ho¹², Onima Chowdhury¹³, Adam Al-Hakim¹⁴, Scott Goldberg¹⁵, Marcela ferrada¹⁶, Sophie georgin-Lavialle¹⁷, Peter Grayson¹⁸, Emma Groarke¹⁹, Bhavisha Patel²⁰, Megan Sullivan²¹, Sarah A. Buckley²², Bryan G. harder²², Sandra Goble²², Matthew Koster¹⁰ and David Beck²³, ¹Vanderbilt University Medical Center, Nashville, TN, ²Institute of Rheumatology, Praha ², Czech Republic, ³The University of Texas MD Anderson Cancer Center, Houston, TX, ⁴University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁶Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, ⁷Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, ⁸Centre Hospitalier Universitaire Toulouse Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France, ⁹Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i³), Saint-Antoine University Hospital, ⁷⁵⁰¹² Paris, France, Paris, France, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Dana Farber Cancer Institute, Boston, MA, ¹²New York University Grossman School of Medicine, VA New York Harbor Health Care System, Brooklyn, NY, ¹³Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, ¹⁴University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine,, Leeds, United Kingdom, ¹⁵New York University Grossman School of Medicine, Brooklyn, NY, ¹⁶University of Maryland, Bethesda, MD, ¹⁷Sorbonne university, Tenon hospital, DMU³ID, CEREMAIA, ERN RITA, Paris, France, ¹⁸National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹⁹National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, ²⁰National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Beltsville, MD, ²¹Mayo Clinic Arizona, Scottsdale, AZ, ²²Sobi Inc., Waltham, MA, ²³Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY
Background/Purpose: VEXAS syndrome is a recently described severe disease characterized by a complex overlap of inflammatory and hematologic features. Due to the severity and refractory…
Abstract Number: 0401 • ACR Convergence 2025
Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
Daniel Lovell¹, Nicolino Ruperto², Jennifer Huggins³, Ekaterina Alexeeva⁴, Colleen Correll⁵, John Bohnsack⁶, Stacey Tarvin⁷, Gabriele Simonini⁸, Thomas Griffin⁹, Andrew Zeft¹⁰, Gerd Horneff¹¹, Pierre Quartier¹², Iionka Orban¹³, Heather Walters¹⁴, Valda Stanevica¹⁵, Julisa Patel¹⁶, Adam M Huber¹⁷, Margalit Rosenkranz¹⁸, Daniel Kingsbury¹⁹, Rosie Scuccimarri²⁰, Gabriel Vega Cornejo²¹, Joost Swart²², Robert Carroll²³, Hermine Brunner¹, Tina Sherrard²⁴, Chiara Pallotti²⁵, Clara Malattia²⁶ and Alberto Martini²⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Università degli Studi Milano-Bicocca, Milan, Italy, ³Cincinnati Children's Medical Center, Cincinnati, OH, ⁴National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Utah, Salt Lake City, UT, ⁷Riley Hospital for Children at Indiana University, Indianapolis, IN, ⁸Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ⁹Atrium Health Levine Children’s Hospital, Charlotte, NC, ¹⁰Cleveland Clinic, Cleveland, OH, ¹¹Asklepios Klinik, Hamburg, Germany, ¹²Hôpital Necker-Enfants Malades, Paris, France, ¹³Department of Rheumatology and Clinical Immunology of Semmelweis University, Budapest, Hungary, ¹⁴Northwell, New Hyde Park, NY, ¹⁵Riga Stradiņš University, Riga, Latvia, ¹⁶Children’s Hospital of Georgia, Augusta University, Augusta, GA, ¹⁷IWK Grace Health Centre, Halifax, NS, Canada, ¹⁸University of Pittsburgh, Pittsburgh, PA, ¹⁹Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ²⁰McGill University Health Centre, Montreal, QC, Canada, ²¹Clinica de reumatología Guadalajara, Guadalajara, Jalisco, Mexico, ²²Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ²³Bristol Myers Squibb, London, United Kingdom, ²⁴Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²⁵Istituto G. Gaslini, Servizio di Sperimentazioni Cliniche Pediatriche, Genova, Italy, ²⁶Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients (pts) with JIA have been…
Abstract Number: 2626 • ACR Convergence 2025
Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)
Yusuf Yazici¹ and Christopher Swearingen², ¹NYU Grossman School of Medicine, La Jolla, CA, ²Biosplice Therapeutics, Inc, San Diego, CA
Background/Purpose: Increased pain and decreased function are hallmarks of knee OA progression. Lorecivivint (LOR), an intra-articular CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways,…
Abstract Number: 2441 • ACR Convergence 2025
Dapirolizumab Pegol Demonstrated Improvement in Quality of Life of Patients with Systemic Lupus Erythematosus: LupusQoL Results from a Phase 3 Trial
Zahi Touma¹, Cynthia Aranow², Ioannis Parodis³, Rosalind Ramsey-Goldman⁴, Matthias Schneider⁵, Christine de La Loge⁶, Teri Jimenez⁷, Mina Nejati⁸ and Laurent arnaud⁹, ¹University of Toronto, Toronto, ON, Canada, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Clinic of Rheumatology and Hiller Research Unit, Heinrich-Heine-University, Düsseldorf, Germany, ⁶UCB, Brussels, Belgium, ⁷UCB, Raleigh, NC, ⁸Biogen, Cambridge, MA, ⁹Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France
Background/Purpose: SLE imposes significant disease burden and diminishes health-related quality of life (HRQoL); improvement of HRQoL is therefore a key treatment goal in SLE.1,2 Dapirolizumab…
Abstract Number: 2289 • ACR Convergence 2025
Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity in Patients with Rheumatoid Arthritis: A Pilot Study
Yuichiro Fujieda¹, Kaoru Murakami², Hiroki Tanaka², Yuichi Kojima², Yuki Kudo¹, Kohei Karino¹, Hiroyuki Nakamura¹, Ryo Hisada¹, Michihito Kono¹, Masaaki Murakami² and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ²Institute for Genetic Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Vagus nerve stimulation (VNS) has emerged as a potential therapeutic strategy for inflammatory diseases by modulating inflammatory reflex pathways. Transcutaneous auricular vagus nerve stimulation…
Abstract Number: 1999 • ACR Convergence 2025
Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials
Herbert Baraf¹, Andrew J. Sulich², Guillermo J. Valenzuela³, Rehan Azeem⁴, Ben Peace⁵, Bhavisha Desai⁶ and Puja Khanna⁷, ¹The Center for Rheumatology and Bone Research, Rheumatology, Wheaton, Maryland, USA; Division of Rheumatology, The George Washington University, Washington, DC, ²Shores Rheumatology, St. Clair Shores, MI, ³Iris Rheumatology, Plantation, FL, ⁴Global MACD, Sobi Inc., Waltham, MA, ⁵Statistical Science, Sobi, Stockholm, Sweden, ⁶Sobi, Glastonbury, CT, ⁷Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Uricase-based therapies may profoundly lower serum uric acid (sUA) in patients (pts) with uncontrolled gout (UG) but often lead to anti-drug antibody (ADA) formation,…
Abstract Number: 1542 • ACR Convergence 2025
Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-Week Phase 3 Trial
Richard Furie¹, George Bertsias², Lucy Carter³, Eric Morand⁴, Marta Mosca⁵, Marilyn Pike⁶, Vanessa Taieb⁷, Annette Nelde⁸, Ed Vital⁹ and Christian Stach¹⁰, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Rheumatology and Clinical Immunology, University Hospital of Heraklion and University of Crete Medical School and Foundation for Research and Technology-Hellas (FORTH), Infections and Immunity, Institute of Molecular Biology and Biotechnology, Heraklion, Greece, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵University of Pisa, Pisa, Pisa, Italy, ⁶Rheumatology, MedPharm Consulting, Inc., Bethesda, MD, ⁷UCB, Colombes, France, ⁸Biogen, Baar, Switzerland, ⁹University of Leeds, Leeds, England, United Kingdom, ¹⁰UCB, Monheim am Rhein, Germany
Background/Purpose: Despite the evolution of various flare definitions and their inclusion in SLE clinical trials, moderate flares tend to be underestimated in trials owing to…
Abstract Number: 1438 • ACR Convergence 2025
Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
Félicie Costantino¹, Ann-Sophie De Craemer², Filip Van den Bosch², Maxime Breban³, Vanessa Taieb⁴, Diana Voiniciuc⁵, Natasha de Peyrecave⁶, Dirk Elewaut⁷ and Maria-Antonietta D'Agostino⁸, ¹Department of Rheumatology, Ambroise Paré Hospital, AP-HP, Paris, France and Infection & Inflammation, UMR ¹¹⁷³, Inserm, UVSQ/Université Paris Saclay, Montigny-Le-Bretonneux, France, ²Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³CHU Ambroise-Paré, Boulogne-Billancourt, France, ⁴UCB, Colombes, France, ⁵UCB, Slough, United Kingdom, ⁶UCB, Brussels, Belgium, ⁷VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁸Department of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease mainly affecting the sacroiliac joints and spine.1 Peripheral manifestations are common, contributing to disease burden.2 Two…

« Previous Page
1
…
5
6
7
8
9
…
55
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].